Massachusetts-based Rapid Micro Biosystems has closed a $120m financing round, led by the new investors Ally Bridge Group and Endeavour Vision.
Existing investors, including Bain Capital Life Sciences, Longitude Capital, Xeraya Capital and Asahi Kasei Medical, also participated in the funding round.
Rapid Micro Biosystems is a crucial player behind the scenes of the pharmaceutical industry; the company provides automated, high-throughput microbial detection technology for manufacturing through its Growth Direct platform.
The company plans to use this $120m of funding to accelerate the global expansion of this technology to meet growing demand, particularly in the context of Covid-19 and its disruption of pharma manufacturing. Importance